5 O
WARNINGS O
AND O
PRECAUTIONS O
EXCERPT O
: O
* O
Estrogens O
increase O
the O
risk O
of O
gallbladder O
disease O
( O
5.4 O
) O
* O
Discontinue O
estrogen O
if O
severe O
hypercalcemia O
, O
loss O
of O
vision O
, O
severe O
hypertriglyceridemia O
or O
cholestatic O
jaundice O
occurs O
( O
5.5 O
, O
5.6 O
, O
5.11 O
, O
5.12 O
) O
* O
Monitor O
thyroid O
function O
in O
women O
on O
thyroid O
replacement O
therapy O
( O
5.13 O
, O
5.18 O
) O
5.1 O
Cardiovascular B-OSE_Labeled_AE
Disorders I-OSE_Labeled_AE
An O
increased O
risk O
of O
stroke B-OSE_Labeled_AE
and O
DVT B-OSE_Labeled_AE
has O
been O
reported O
with O
estrogen-alone O
therapy O
. O

An O
increased O
risk O
of O
PE B-NonOSE_AE
, O
DVT B-NonOSE_AE
, O
stroke B-NonOSE_AE
and O
MI B-NonOSE_AE
has O
been O
reported O
with O
estrogen O
plus O
progestin O
therapy O
. O

Should O
any O
of O
these O
events O
occur O
or O
be O
suspected O
, O
estrogen O
with O
or O
without O
progestin O
therapy O
should O
be O
discontinued O
immediately O
. O

Risk O
factors O
for O
arterial B-Not_AE_Candidate
vascular I-Not_AE_Candidate
disease I-Not_AE_Candidate
( O
for O
example O
, O
hypertension B-Not_AE_Candidate
, O
diabetes B-Not_AE_Candidate
mellitus I-Not_AE_Candidate
, O
tobacco B-Not_AE_Candidate
use I-Not_AE_Candidate
, O
hypercholesterolemia B-Not_AE_Candidate
, O
and O
obesity B-Not_AE_Candidate
) O
and/or O
venous B-Not_AE_Candidate
thromboembolism I-Not_AE_Candidate
( I-Not_AE_Candidate
VTE I-Not_AE_Candidate
) O
( O
for O
example O
, O
personal O
or O
family O
history O
of O
VTE B-Not_AE_Candidate
, O
obesity B-Not_AE_Candidate
, O
and O
systemic B-Not_AE_Candidate
lupus I-Not_AE_Candidate
erythematosus I-Not_AE_Candidate
) O
should O
be O
managed O
appropriately O
. O

Stroke O
In O
the O
WHI O
estrogen-alone O
substudy O
, O
a O
statistically O
significant O
increased O
risk O
of O
stroke B-OSE_Labeled_AE
was O
reported O
in O
women O
50 O
to O
79 O
years O
of O
age O
receiving O
daily O
CE O
( O
0.625 O
mg O
) O
-alone O
compared O
to O
women O
in O
the O
same O
age O
group O
receiving O
placebo O
( O
45 O
versus O
33 O
per O
10,000 O
women-years O
) O
. O

The O
increase O
in O
risk O
was O
demonstrated O
in O
year O
1 O
and O
persisted O
[ O
see O
Clinical O
Studies O
( O
14.5 O
) O
] O
. O

Should O
a O
stroke B-NonOSE_AE
occur O
or O
be O
suspected O
, O
estrogen-alone O
therapy O
should O
be O
discontinued O
immediately O
. O

Subgroup O
analyses O
of O
women O
50 O
to O
59 O
years O
of O
age O
suggest O
no O
increased O
risk O
of O
stroke B-NonOSE_AE
for O
those O
women O
receiving O
CE O
( O
0.625 O
mg O
) O
-alone O
versus O
those O
receiving O
placebo O
( O
18 O
versus O
21 O
per O
10,000 O
women-years O
) O
. O

1 O
In O
the O
WHI O
estrogen O
plus O
progestin O
substudy O
, O
a O
statistically O
significant O
increased O
risk O
of O
stroke B-NonOSE_AE
was O
reported O
in O
women O
50 O
to O
79 O
years O
of O
age O
receiving O
daily O
CE O
( O
0.625 O
mg O
) O
plus O
MPA O
( O
2.5 O
mg O
) O
compared O
to O
women O
in O
the O
same O
age O
group O
receiving O
placebo O
( O
33 O
versus O
25 O
per O
10,000 O
women-years O
) O
[ O
see O
Clinical O
Studies O
( O
14.5 O
) O
] O
. O

The O
increase O
in O
risk O
was O
demonstrated O
after O
the O
first O
year O
and O
persisted O
. O

1 O
Should O
a O
stroke B-NonOSE_AE
occur O
or O
be O
suspected O
, O
estrogen O
plus O
progestin O
therapy O
should O
be O
discontinued O
immediately O
. O

Coronary O
Heart O
Disease O
In O
the O
WHI O
estrogen-alone O
substudy O
, O
no O
overall O
effect O
on O
coronary B-NonOSE_AE
heart I-NonOSE_AE
disease I-NonOSE_AE
( I-NonOSE_AE
CHD I-NonOSE_AE
) O
events O
( O
defined O
as O
nonfatal O
MI B-NonOSE_AE
, O
silent B-NonOSE_AE
MI I-NonOSE_AE
, O
or O
CHD B-NonOSE_AE
death I-NonOSE_AE
) O
was O
reported O
in O
women O
receiving O
estrogen-alone O
compared O
to O
placebo O
2 O
[ O
see O
Clinical O
Studies O
( O
14.5 O
) O
] O
. O

Subgroup O
analyses O
of O
women O
50 O
to O
59 O
years O
of O
age O
suggest O
a O
statistically O
non-significant O
reduction O
in O
CHD B-NonOSE_AE
events O
( O
CE O
[ O
0.625 O
mg O
] O
-alone O
compared O
to O
placebo O
) O
in O
women O
with O
less O
than O
10 O
years O
since O
menopause B-Not_AE_Candidate
( O
8 O
versus O
16 O
per O
10,000 O
women-years O
) O
. O

1 O
In O
the O
WHI O
estrogen O
plus O
progestin O
substudy O
, O
there O
was O
a O
statistically O
non-significant O
increased O
risk O
of O
CHD B-NonOSE_AE
events O
reported O
in O
women O
receiving O
daily O
CE O
( O
0.625 O
mg O
) O
plus O
MPA O
( O
2.5 O
mg O
) O
compared O
to O
women O
receiving O
placebo O
( O
41 O
versus O
34 O
per O
10,000 O
women-years O
) O
. O

1 O
An O
increase O
in O
relative O
risk O
was O
demonstrated O
in O
year O
1 O
, O
and O
a O
trend O
toward O
decreasing O
relative O
risk O
was O
reported O
in O
years O
2 O
through O
5 O
[ O
see O
Clinical O
Studies O
( O
14.5 O
) O
] O
. O

In O
postmenopausal B-Not_AE_Candidate
women O
with O
documented O
heart B-Not_AE_Candidate
disease I-Not_AE_Candidate
( O
n O
= O
2,763 O
, O
average O
66.7 O
years O
of O
age O
) O
, O
in O
a O
controlled O
clinical O
trial O
of O
secondary O
prevention O
of O
cardiovascular B-Not_AE_Candidate
disease I-Not_AE_Candidate
( O
Heart O
and O
Estrogen/Progestin O
Replacement O
Study O
; O
HERS O
) O
, O
treatment O
with O
daily O
CE O
( O
0.625 O
mg O
) O
plus O
MPA O
( O
2.5 O
mg O
) O
demonstrated O
no O
cardiovascular O
benefit O
. O

During O
an O
average O
follow-up O
of O
4.1 O
years O
, O
treatment O
with O
CE O
plus O
MPA O
did O
not O
reduce O
the O
overall O
rate O
of O
CHD B-NonOSE_AE
events O
in O
postmenopausal B-Not_AE_Candidate
women O
with O
established O
CHD B-Not_AE_Candidate
. O

There O
were O
more O
CHD B-NonOSE_AE
events O
in O
the O
CE O
plus O
MPA-treated O
group O
than O
in O
the O
placebo O
group O
in O
year O
1 O
, O
but O
not O
during O
the O
subsequent O
years O
. O

Two O
thousand O
, O
three O
hundred O
and O
twenty-one O
( O
2,321 O
) O
women O
from O
the O
original O
HERS O
trial O
agreed O
to O
participate O
in O
an O
open O
label O
extension O
of O
HERS O
, O
HERS O
II O
. O

Average O
follow-up O
in O
HERS O
II O
was O
an O
additional O
2.7 O
years O
, O
for O
a O
total O
of O
6.8 O
years O
overall O
. O

Rates O
of O
CHD B-NonOSE_AE
events I-NonOSE_AE
were O
comparable O
among O
women O
in O
the O
CE O
( O
0.625 O
mg O
) O
plus O
MPA O
( O
2.5 O
mg O
) O
group O
and O
the O
placebo O
group O
in O
HERS O
, O
HERS O
II O
, O
and O
overall O
. O

Venous O
Thromboembolism O
( O
VTE O
) O
In O
the O
WHI O
estrogen-alone O
substudy O
, O
the O
risk O
of O
VTE B-OSE_Labeled_AE
( O
DVT B-OSE_Labeled_AE
and O
PE B-OSE_Labeled_AE
) O
, O
was O
increased O
for O
women O
receiving O
daily O
CE O
( O
0.625 O
mg O
) O
-alone O
compared O
to O
placebo O
( O
30 O
versus O
22 O
per O
10,000 O
women-years O
) O
, O
although O
only O
the O
increased O
risk O
of O
DVT B-OSE_Labeled_AE
reached O
statistical O
significance O
( O
23 O
versus O
15 O
per O
10,000 O
women-years O
) O
. O

The O
increase O
in O
VTE B-OSE_Labeled_AE
risk O
was O
demonstrated O
during O
the O
first O
2 O
years O
3 O
[ O
see O
Clinical O
Studies O
( O
14.5 O
) O
] O
. O

Should O
a O
VTE B-NonOSE_AE
occur O
or O
be O
suspected O
, O
estrogen-alone O
therapy O
should O
be O
discontinued O
immediately O
. O

In O
the O
WHI O
estrogen O
plus O
progestin O
substudy O
, O
a O
statistically O
significant O
2-fold O
greater O
rate O
of O
VTE B-NonOSE_AE
was O
reported O
in O
women O
receiving O
daily O
CE O
( O
0.625 O
mg O
) O
plus O
MPA O
( O
2.5 O
mg O
) O
compared O
to O
women O
receiving O
placebo O
( O
35 O
versus O
17 O
per O
10,000 O
women-years O
) O
. O

Statistically O
significant O
increases O
in O
risk O
for O
both O
DVT B-NonOSE_AE
( O
26 O
versus O
13 O
per O
10,000 O
women-years O
) O
and O
PE B-NonOSE_AE
( O
18 O
versus O
8 O
per O
10,000 O
women-years O
) O
were O
also O
demonstrated O
. O

The O
increase O
in O
VTE B-NonOSE_AE
risk O
was O
demonstrated O
during O
the O
first O
year O
and O
persisted O
4 O
[ O
see O
Clinical O
Studies O
( O
14.5 O
) O
] O
. O

Should O
a O
VTE B-NonOSE_AE
occur O
or O
be O
suspected O
, O
estrogen O
plus O
progestin O
therapy O
should O
be O
discontinued O
immediately O
. O

If O
feasible O
, O
estrogens O
should O
be O
discontinued O
at O
least O
4 O
to O
6 O
weeks O
before O
surgery O
of O
the O
type O
associated O
with O
an O
increased O
risk O
of O
thromboembolism B-NonOSE_AE
, O
or O
during O
periods O
of O
prolonged O
immobilization O
. O

5.2 O
Malignant B-OSE_Labeled_AE
Neoplasms I-OSE_Labeled_AE
Endometrial O
Cancer O
An O
increased O
risk O
of O
endometrial B-OSE_Labeled_AE
cancer I-OSE_Labeled_AE
has O
been O
reported O
with O
the O
use O
of O
unopposed O
estrogen O
therapy O
in O
a O
woman O
with O
a O
uterus O
. O

The O
reported O
endometrial B-OSE_Labeled_AE
cancer I-OSE_Labeled_AE
risk O
among O
unopposed O
estrogen O
users O
is O
about O
2 O
to O
12 O
times O
greater O
than O
in O
non-users O
, O
and O
appears O
dependent O
on O
duration O
of O
treatment O
and O
on O
estrogen O
dose O
. O

Most O
studies O
show O
no O
significant O
increased O
risk O
associated O
with O
use O
of O
estrogens O
for O
less O
than O
1 O
year O
. O

The O
greatest O
risk O
appears O
associated O
with O
prolonged O
use O
, O
with O
increased O
risks O
of O
15- O
to O
24-fold O
for O
5 O
to O
10 O
years O
or O
more O
, O
and O
this O
risk O
has O
been O
shown O
to O
persist O
for O
at O
least O
8 O
to O
15 O
years O
after O
estrogen O
therapy O
is O
discontinued O
. O

Clinical O
surveillance O
of O
all O
women O
using O
estrogen-alone O
or O
estrogen O
plus O
progestin O
therapy O
is O
important O
. O

Adequate O
diagnostic O
measures O
, O
including O
directed O
or O
random O
endometrial O
sampling O
when O
indicated O
, O
should O
be O
undertaken O
to O
rule O
out O
malignancy B-NonOSE_AE
in O
postmenopausal B-Not_AE_Candidate
women O
with O
undiagnosed O
persistent O
or O
recurring O
abnormal O
genital B-Not_AE_Candidate
bleeding I-Not_AE_Candidate
. O

There O
is O
no O
evidence O
that O
the O
use O
of O
natural O
estrogens O
results O
in O
a O
different O
endometrial O
risk O
profile O
than O
synthetic O
estrogens O
of O
equivalent O
estrogen O
dose O
. O

Adding O
a O
progestin O
to O
postmenopausal B-NonOSE_AE
estrogen O
therapy O
has O
been O
shown O
to O
reduce O
the O
risk O
of O
endometrial B-NonOSE_AE
hyperplasia I-NonOSE_AE
, O
which O
may O
be O
a O
precursor O
to O
endometrial B-NonOSE_AE
cancer I-NonOSE_AE
. O

Breast O
Cancer O
The O
most O
important O
randomized O
clinical O
trial O
providing O
information O
about O
breast B-NonOSE_AE
cancer I-NonOSE_AE
in O
estrogen-alone O
users O
is O
the O
WHI O
substudy O
of O
daily O
CE O
( O
0.625 O
mg O
) O
-alone O
. O

In O
the O
WHI O
estrogen-alone O
substudy O
, O
after O
an O
average O
follow-up O
of O
7.1 O
years O
, O
daily O
CE O
( O
0.625 O
mg O
) O
-alone O
was O
not O
associated O
with O
an O
increased O
risk O
of O
invasive B-NonOSE_AE
breast I-NonOSE_AE
cancer I-NonOSE_AE
[ O
relative O
risk O
( O
RR O
) O
0.80 O
] O
5 O
[ O
see O
Clinical O
Studies O
( O
14.5 O
) O
] O
. O

The O
most O
important O
randomized O
clinical O
trial O
providing O
information O
about O
breast B-NonOSE_AE
cancer I-NonOSE_AE
in O
estrogen O
plus O
progestin O
users O
is O
the O
WHI O
substudy O
of O
daily O
CE O
( O
0.625 O
mg O
) O
plus O
MPA O
( O
2.5 O
mg O
) O
. O

After O
a O
mean O
follow-up O
of O
5.6 O
years O
, O
the O
estrogen O
plus O
progestin O
substudy O
reported O
an O
increased O
risk O
of O
invasive B-NonOSE_AE
breast I-NonOSE_AE
cancer I-NonOSE_AE
in O
women O
who O
took O
daily O
CE O
plus O
MPA O
. O

In O
this O
substudy O
, O
prior O
use O
of O
estrogen-alone O
or O
estrogen O
plus O
progestin O
therapy O
was O
reported O
by O
26 O
percent O
of O
the O
women O
. O

The O
relative O
risk O
of O
invasive B-NonOSE_AE
breast I-NonOSE_AE
cancer I-NonOSE_AE
was O
1.24 O
, O
and O
the O
absolute O
risk O
was O
41 O
versus O
33 O
cases O
per O
10,000 O
women-years O
, O
for O
CE O
plus O
MPA O
compared O
with O
placebo O
. O

6 O
Among O
women O
who O
reported O
prior O
use O
of O
hormone O
therapy O
, O
the O
relative O
risk O
of O
invasive B-NonOSE_AE
breast I-NonOSE_AE
cancer I-NonOSE_AE
was O
1.86 O
, O
and O
the O
absolute O
risk O
was O
46 O
versus O
25 O
cases O
per O
10,000 O
women-years O
for O
CE O
plus O
MPA O
compared O
with O
placebo O
. O

Among O
women O
who O
reported O
no O
prior O
use O
of O
hormone O
therapy O
, O
the O
relative O
risk O
of O
invasive B-NonOSE_AE
breast I-NonOSE_AE
cancer I-NonOSE_AE
was O
1.09 O
, O
and O
the O
absolute O
risk O
was O
40 O
versus O
36 O
cases O
per O
10,000 O
women-years O
for O
CE O
plus O
MPA O
compared O
with O
placebo O
. O

In O
the O
same O
substudy O
, O
invasive B-NonOSE_AE
breast I-NonOSE_AE
cancers I-NonOSE_AE
were O
larger O
, O
were O
more O
likely O
to O
be O
node O
positive O
, O
and O
were O
diagnosed O
at O
a O
more O
advanced O
stage O
in O
the O
CE O
( O
0.625 O
mg O
) O
plus O
MPA O
( O
2.5 O
mg O
) O
group O
compared O
with O
the O
placebo O
group O
. O

Metastatic O
disease O
was O
rare O
, O
with O
no O
apparent O
difference O
between O
the O
two O
groups O
. O

Other O
prognostic O
factors O
, O
such O
as O
histologic O
subtype O
, O
grade O
and O
hormone O
receptor O
status O
did O
not O
differ O
between O
the O
groups O
[ O
see O
Clinical O
Studies O
( O
14.5 O
) O
] O
. O

Consistent O
with O
the O
WHI O
clinical O
trial O
, O
observational O
studies O
have O
also O
reported O
an O
increased O
risk O
of O
breast B-OSE_Labeled_AE
cancer I-OSE_Labeled_AE
for O
estrogen O
plus O
progestin O
therapy O
, O
and O
a O
smaller O
increased O
risk O
for O
estrogen-alone O
therapy O
, O
after O
several O
years O
of O
use O
. O

The O
risk O
increased O
with O
duration O
of O
use O
, O
and O
appeared O
to O
return O
to O
baseline O
over O
about O
5 O
years O
after O
stopping O
treatment O
( O
only O
the O
observational O
studies O
have O
substantial O
data O
on O
risk O
after O
stopping O
) O
. O

Observational O
studies O
also O
suggest O
that O
the O
risk O
of O
breast B-NonOSE_AE
cancer I-NonOSE_AE
was O
greater O
, O
and O
became O
apparent O
earlier O
, O
with O
estrogen O
plus O
progestin O
therapy O
as O
compared O
to O
estrogen-alone O
therapy O
. O

However O
, O
these O
studies O
have O
not O
found O
significant O
variation O
in O
the O
risk O
of O
breast B-NonOSE_AE
cancer I-NonOSE_AE
among O
different O
estrogen O
plus O
progestin O
combinations O
, O
doses O
, O
or O
routes O
of O
administration O
. O

The O
use O
of O
estrogen-alone O
and O
estrogen O
plus O
progestin O
has O
been O
reported O
to O
result O
in O
an O
increase O
in O
abnormal B-OSE_Labeled_AE
mammograms I-OSE_Labeled_AE
, O
requiring O
further O
evaluation O
. O

All O
women O
should O
receive O
yearly O
breast O
examinations O
by O
a O
healthcare O
provider O
and O
perform O
monthly O
breast O
self-examinations O
. O

In O
addition O
, O
mammography O
examinations O
should O
be O
scheduled O
based O
on O
patient O
age O
, O
risk O
factors O
, O
and O
prior O
mammogram O
results O
. O

Ovarian O
Cancer O
The O
WHI O
estrogen O
plus O
progestin O
substudy O
reported O
a O
statistically O
non-significant O
increased O
risk O
of O
ovarian B-NonOSE_AE
cancer I-NonOSE_AE
. O

After O
an O
average O
follow-up O
of O
5.6 O
years O
, O
the O
relative O
risk O
for O
ovarian B-NonOSE_AE
cancer I-NonOSE_AE
for O
CE O
plus O
MPA O
versus O
placebo O
was O
1.58 O
( O
95 O
percent O
CI O
0.77-3.24 O
) O
. O

The O
absolute O
risk O
for O
CE O
plus O
MPA O
versus O
placebo O
was O
4 O
versus O
3 O
cases O
per O
10,000 O
women-years O
. O

7 O
A O
meta-analysis O
of O
17 O
prospective O
and O
35 O
retrospective O
epidemiology O
studies O
found O
that O
women O
who O
used O
hormonal O
therapy O
for O
menopausal B-Not_AE_Candidate
symptoms I-Not_AE_Candidate
had O
an O
increased O
risk O
for O
ovarian B-OSE_Labeled_AE
cancer I-OSE_Labeled_AE
. O

The O
primary O
analysis O
, O
using O
case-control O
comparisons O
, O
included O
12,110 O
cancer B-NonOSE_AE
cases O
from O
the O
17 O
prospective O
studies O
. O

The O
relative O
risks O
associated O
with O
current O
use O
of O
hormonal O
therapy O
was O
1.41 O
( O
95 O
% O
confidence O
interval O
[ O
CI O
] O
1.32 O
to O
1.50 O
) O
; O
there O
was O
no O
difference O
in O
the O
risk O
estimates O
by O
duration O
of O
the O
exposure O
( O
less O
than O
5 O
years O
[ O
median O
of O
3 O
years O
] O
vs O
. O
greater O
than O
5 O
years O
[ O
median O
of O
10 O
years O
] O
of O
use O
before O
the O
cancer B-NonOSE_AE
diagnosis O
) O
. O

The O
relative O
risk O
associated O
with O
combined O
current O
and O
recent O
use O
( O
discontinued O
use O
within O
5 O
years O
before O
cancer B-NonOSE_AE
diagnosis O
) O
was O
1.37 O
( O
95 O
% O
CI O
1.27-1.48 O
) O
, O
and O
the O
elevated O
risk O
was O
significant O
for O
both O
estrogen-alone O
and O
estrogen O
plus O
progestin O
products O
. O

The O
exact O
duration O
of O
hormone O
therapy O
use O
associated O
with O
an O
increased O
risk O
of O
ovarian B-NonOSE_AE
cancer I-NonOSE_AE
, O
however O
, O
is O
unknown O
. O

5.3 O
Probable O
Dementia O
In O
the O
WHIMS O
estrogen-alone O
ancillary O
study O
of O
WHI O
, O
a O
population O
of O
2,947 O
hysterectomized O
women O
65 O
to O
79 O
years O
of O
age O
was O
randomized O
to O
daily O
CE O
( O
0.625 O
mg O
) O
-alone O
or O
placebo O
. O

After O
an O
average O
follow-up O
of O
5.2 O
years O
, O
28 O
women O
in O
the O
estrogen-alone O
group O
and O
19 O
women O
in O
the O
placebo O
group O
were O
diagnosed O
with O
probable O
dementia B-OSE_Labeled_AE
. O

The O
relative O
risk O
of O
probable O
dementia B-OSE_Labeled_AE
for O
CE-alone O
versus O
placebo O
was O
1.49 O
( O
95 O
percent O
CI O
0.83-2.66 O
) O
. O

The O
absolute O
risk O
of O
probable O
dementia B-OSE_Labeled_AE
for O
CE-alone O
versus O
placebo O
was O
37 O
versus O
25 O
cases O
per O
10,000 O
women-years O
8 O
[ O
see O
Use O
in O
Specific O
Populations O
( O
8.5 O
) O
, O
and O
Clinical O
Studies O
( O
14.6 O
) O
] O
. O

In O
the O
WHIMS O
estrogen O
plus O
progestin O
ancillary O
study O
of O
WHI O
, O
a O
population O
of O
4,532 O
postmenopausal B-Not_AE_Candidate
women O
65 O
to O
79 O
years O
of O
age O
was O
randomized O
to O
daily O
CE O
( O
0.625 O
mg O
) O
plus O
MPA O
( O
2.5 O
mg O
) O
or O
placebo O
. O

After O
an O
average O
follow-up O
of O
4 O
years O
, O
40 O
women O
in O
the O
CE O
plus O
MPA O
group O
and O
21 O
women O
in O
the O
placebo O
group O
were O
diagnosed O
with O
probable O
dementia B-NonOSE_AE
. O

The O
relative O
risk O
of O
probable O
dementia B-NonOSE_AE
for O
CE O
plus O
MPA O
versus O
placebo O
was O
2.05 O
( O
95 O
percent O
CI O
1.21-3.48 O
) O
. O

The O
absolute O
risk O
of O
probable O
dementia B-NonOSE_AE
for O
CE O
plus O
MPA O
versus O
placebo O
was O
45 O
versus O
22 O
cases O
per O
10,000 O
women-years O
8 O
[ O
see O
Use O
in O
Specific O
Populations O
( O
8.5 O
) O
, O
and O
Clinical O
Studies O
( O
14.6 O
) O
] O
. O

When O
data O
from O
the O
two O
populations O
in O
the O
WHIMS O
estrogen-alone O
and O
estrogen O
plus O
progestin O
ancillary O
studies O
were O
pooled O
as O
planned O
in O
the O
WHIMS O
protocol O
, O
the O
reported O
overall O
relative O
risk O
for O
probable O
dementia B-OSE_Labeled_AE
was O
1.76 O
( O
95 O
percent O
CI O
1.19-2.60 O
) O
. O

Since O
both O
ancillary O
studies O
were O
conducted O
in O
women O
65 O
to O
79 O
years O
of O
age O
, O
it O
is O
unknown O
whether O
these O
findings O
apply O
to O
younger O
postmenopausal B-Not_AE_Candidate
women O
8 O
[ O
see O
Use O
in O
Specific O
Populations O
( O
8.5 O
) O
, O
and O
Clinical O
Studies O
( O
14.6 O
) O
] O
. O

5.4 O
Gallbladder O
Disease O
A O
2- O
to O
4-fold O
increase O
in O
the O
risk O
of O
gallbladder B-OSE_Labeled_AE
disease I-OSE_Labeled_AE
requiring O
surgery O
in O
postmenopausal B-Not_AE_Candidate
women O
receiving O
estrogens O
has O
been O
reported O
. O

5.5 O
Hypercalcemia O
Estrogen O
administration O
may O
lead O
to O
severe O
hypercalcemia B-OSE_Labeled_AE
in O
patients O
with O
breast B-Not_AE_Candidate
cancer I-Not_AE_Candidate
and O
bone B-Not_AE_Candidate
metastases I-Not_AE_Candidate
. O

If O
hypercalcemia B-NonOSE_AE
occurs O
, O
use O
of O
the O
drug O
should O
be O
stopped O
and O
appropriate O
measures O
taken O
to O
reduce B-NonOSE_AE
the I-NonOSE_AE
serum I-NonOSE_AE
calcium I-NonOSE_AE
level I-NonOSE_AE
. O

5.6 O
Visual B-OSE_Labeled_AE
Abnormalities I-OSE_Labeled_AE
Retinal B-OSE_Labeled_AE
vascular I-OSE_Labeled_AE
thrombosis I-OSE_Labeled_AE
has O
been O
reported O
in O
patients O
receiving O
estrogens O
. O

Discontinue O
medication O
pending O
examination O
if O
there O
is O
sudden O
partial B-NonOSE_AE
or O
complete O
loss I-NonOSE_AE
of I-NonOSE_AE
vision I-NonOSE_AE
, O
or O
a O
sudden O
onset O
of O
proptosis B-NonOSE_AE
, O
diplopia B-NonOSE_AE
, O
or O
migraine B-NonOSE_AE
. O

If O
examination O
reveals O
papilledema B-NonOSE_AE
or O
retinal B-NonOSE_AE
vascular I-NonOSE_AE
lesions I-NonOSE_AE
, O
estrogens O
should O
be O
permanently O
discontinued O
. O

5.7 O
Anaphylactic O
Reaction O
and O
Angioedema O
Cases O
of O
anaphylaxis B-OSE_Labeled_AE
, O
which O
developed O
within O
minutes O
to O
hours O
after O
taking O
PREMARIN O
and O
require O
emergency O
medical O
management O
, O
have O
been O
reported O
in O
the O
postmarketing O
setting O
. O

Skin B-OSE_Labeled_AE
( O
hives O
, O
pruritis O
, O
sw O
ollen B-OSE_Labeled_AE
l O
ips B-OSE_Labeled_AE
- I-OSE_Labeled_AE
tong I-OSE_Labeled_AE
ue O
- B-OSE_Labeled_AE
face I-OSE_Labeled_AE
) I-OSE_Labeled_AE
and I-OSE_Labeled_AE
e I-OSE_Labeled_AE
ither O
respiratory O
tract O
( O
respiratory B-OSE_Labeled_AE
compr I-OSE_Labeled_AE
omise O
) O
or O
gastrointestinal O
tract O
( O
abdominal O
pain O
, O
vomiting O
) O
involveme B-OSE_Labeled_AE
n I-OSE_Labeled_AE
t I-OSE_Labeled_AE
  I-OSE_Labeled_AE
I-O I-OSE_Labeled_AE
S I-OSE_Labeled_AE
E I-OSE_Labeled_AE
_ O
Labele O
d B-OSE_Labeled_AE
  I-OSE_Labeled_AE
I I-OSE_Labeled_AE
- I-OSE_Labeled_AE
OSE I-OSE_Labeled_AE
_ I-OSE_Labeled_AE
Labeled I-OSE_Labeled_AE
_ I-OSE_Labeled_AE
AE I-OSE_Labeled_AE
_ I-OSE_Labeled_AE
  I-OSE_Labeled_AE
I-OSE_Labeled_AE O
AE I-OSE_L
abeled I-OSE_Labeled_AE
_ I-O
SE B-OSE_Labeled_AE
_ I-OSE_Labeled_AE
Labeled I-OSE_Labeled_AE
_ I-OSE_Labeled_AE
AE I-OSE_Labeled_AE
A O
E B-OSE_Labeled_AE
  I-OSE_Labeled_AE
I I-OSE_Labeled_AE
- I-OSE_Labeled_AE
OSE I-OSE_Labeled_AE
_ I-OSE_Labeled_AE
Labeled_AE O
has O
been O
noted O
. O

Angioedema B-OSE_Labeled_AE
involving O
the O
tongue O
, O
larynx O
, O
face O
, O
hands O
, O
and O
feet O
requiring O
medical O
intervention O
has O
occurred O
postmarketing O
in O
patients O
taking O
PREMARIN O
. O

If O
angioedema B-NonOSE_AE
involves O
the O
tongue O
, O
glottis O
, O
or O
larynx O
, O
airway B-NonOSE_AE
obstruction I-NonOSE_AE
may O
occur O
. O

Patients O
who O
develop O
an O
anaphylactic B-NonOSE_AE
reaction I-NonOSE_AE
with O
or O
without O
angioedema B-NonOSE_AE
after O
treatment O
with O
PREMARIN O
should O
not O
receive O
PREMARIN O
again O
. O

5.8 O
Addition O
of O
a O
Progestin O
When O
a O
Woman O
Has O
Not O
Had O
a O
Hysterectomy O
Studies O
of O
the O
addition O
of O
a O
progestin O
for O
10 O
or O
more O
days O
of O
a O
cycle O
of O
estrogen O
administration O
or O
daily O
with O
estrogen O
in O
a O
continuous O
regimen O
, O
have O
reported O
a O
lowered O
incidence O
of O
endometrial B-NonOSE_AE
hyperplasia I-NonOSE_AE
than O
would O
be O
induced O
by O
estrogen O
treatment O
alone O
. O

Endometrial B-NonOSE_AE
hyperplasia I-NonOSE_AE
may O
be O
a O
precursor O
to O
endometrial B-NonOSE_AE
cancer I-NonOSE_AE
. O

There O
are O
, O
however O
, O
possible O
risks O
that O
may O
be O
associated O
with O
the O
use O
of O
progestins O
with O
estrogens O
compared O
to O
estrogen-alone O
regimens O
. O

These O
include O
an O
increased O
risk O
of O
breast B-NonOSE_AE
cancer I-NonOSE_AE
. O

5.9 O
Elevated O
Blood O
Pressure O
In O
a O
small O
number O
of O
case O
reports O
, O
substantial O
increases B-OSE_Labeled_AE
in I-OSE_Labeled_AE
blood I-OSE_Labeled_AE
pressure I-OSE_Labeled_AE
have O
been O
attributed O
to O
idiosyncratic O
reactions O
to O
estrogens O
. O

In O
a O
large O
, O
randomized O
, O
placebo-controlled O
clinical O
trial O
, O
a O
generalized O
effect O
of O
estrogen O
therapy O
on O
blood O
pressure O
was O
not O
seen O
. O

5.10 O
Hypertriglyceridemia O
In O
women O
with O
pre-existing O
hypertriglyceridemia B-Not_AE_Candidate
, O
estrogen O
therapy O
may O
be O
associated O
with O
elevations B-OSE_Labeled_AE
of I-OSE_Labeled_AE
plasma I-OSE_Labeled_AE
triglycerides I-OSE_Labeled_AE
leading O
to O
pancreatitis B-NonOSE_AE
. O

Consider O
discontinuation O
of O
treatment O
if O
pancreatitis B-NonOSE_AE
occurs O
. O

5.11 O
Hepatic O
Impairment O
and/or O
Past O
History O
of O
Cholestatic O
Jaundice O
Estrogens O
may O
be O
poorly O
metabolized O
in O
patients O
with O
impaired B-Not_AE_Candidate
liver I-Not_AE_Candidate
function I-Not_AE_Candidate
. O

For O
women O
with O
a O
history O
of O
cholestatic B-Not_AE_Candidate
jaundice I-Not_AE_Candidate
associated O
with O
past O
estrogen O
use O
or O
with O
pregnancy B-Not_AE_Candidate
, O
caution O
should O
be O
exercised O
, O
and O
in O
the O
case O
of O
recurrence O
, O
medication O
should O
be O
discontinued O
. O

5.12 O
Hypothyroidism O
Estrogen O
administration O
leads O
to O
increased B-OSE_Labeled_AE
thyroid I-OSE_Labeled_AE
- I-OSE_Labeled_AE
binding I-OSE_Labeled_AE
globulin I-OSE_Labeled_AE
( I-OSE_Labeled_AE
TBG I-OSE_Labeled_AE
) I-OSE_Labeled_AE
levels I-OSE_Labeled_AE
. O

Women O
with O
normal O
thyroid O
function O
can O
compensate O
for O
the O
increased B-NonOSE_AE
TBG I-NonOSE_AE
by O
making O
more O
thyroid O
hormone O
, O
thus O
maintaining O
free O
T4and O
T3serum O
concentrations O
in O
the O
normal O
range O
. O

Women O
dependent O
on O
thyroid O
hormone O
replacement O
therapy O
who O
are O
also O
receiving O
estrogens O
may O
require O
increased O
doses O
of O
their O
thyroid O
replacement O
therapy O
. O

These O
women O
should O
have O
their O
thyroid O
function O
monitored O
in O
order O
to O
maintain O
their O
free O
thyroid O
hormone O
levels O
in O
an O
acceptable O
range O
. O

5.13 O
Fluid O
Retention O
Estrogens O
may O
cause O
some O
degree O
of O
fluid B-OSE_Labeled_AE
retention I-OSE_Labeled_AE
. O

Women O
with O
conditions O
that O
might O
be O
influenced O
by O
this O
factor O
, O
such O
as O
cardiac B-Not_AE_Candidate
or O
renal O
dysfunction I-Not_AE_Candidate
, O
warrant O
careful O
observation O
when O
estrogen O
alone O
is O
prescribed O
. O

5.14 O
Hypocalcemia O
Estrogen O
therapy O
should O
be O
used O
with O
caution O
in O
individuals O
with O
hypoparathyroidism B-Not_AE_Candidate
as O
estrogen-induced O
hypocalcemia B-OSE_Labeled_AE
may O
occur O
. O

5.15 O
Hereditary O
Angioedema O
Exogenous O
estrogens O
may O
exacerbate B-OSE_Labeled_AE
symptoms I-OSE_Labeled_AE
of I-OSE_Labeled_AE
angioedema I-OSE_Labeled_AE
in O
women O
with O
hereditary B-Not_AE_Candidate
angioedema I-Not_AE_Candidate
. O

5.16 O
Exacerbation B-OSE_Labeled_AE
of I-OSE_Labeled_AE
Endometriosis I-OSE_Labeled_AE
A O
few O
cases O
of O
malignant B-OSE_Labeled_AE
transformation I-OSE_Labeled_AE
of I-OSE_Labeled_AE
residual I-OSE_Labeled_AE
endometrial I-OSE_Labeled_AE
implants I-OSE_Labeled_AE
have O
been O
reported O
in O
women O
treated O
post-hysterectomy O
with O
estrogen-alone O
therapy O
. O

For O
women O
known O
to O
have O
residual O
endometriosis B-Not_AE_Candidate
post-hysterectomy O
, O
the O
addition O
of O
progestin O
should O
be O
considered O
. O

5.17 O
Exacerbation O
of O
Other O
Conditions O
Estrogen O
therapy O
may O
cause O
an O
exacerbation B-OSE_Labeled_AE
of I-OSE_Labeled_AE
asthma I-OSE_Labeled_AE
, O
diabetes O
mellitus O
, O
epilepsy O
, O
migraine O
, O
porphyria O
, O
systemic O
lupus O
erythematosus O
, O
and O
hepatic O
hemangiomas O
and O
should O
be O
used O
with O
caution O
in O
women O
with O
these O
conditions O
. O

5.18 O
Laboratory O
Tests O
Serum O
follicle O
stimulating O
hormone O
( O
FSH O
) O
and O
estradiol O
levels O
have O
not O
been O
shown O
to O
be O
useful O
in O
the O
management O
of O
moderate O
to O
severe O
vasomotor B-Not_AE_Candidate
symptoms I-Not_AE_Candidate
and O
moderate O
to O
severe O
symptoms O
of O
vulvar B-Not_AE_Candidate
and O
vaginal O
atrophy I-Not_AE_Candidate
. O

Laboratory O
parameters O
may O
be O
useful O
in O
guiding O
dosage O
for O
the O
treatment O
of O
hypoestrogenism B-Not_AE_Candidate
due O
to O
hypogonadism B-Not_AE_Candidate
, O
castration O
and O
primary B-Not_AE_Candidate
ovarian I-Not_AE_Candidate
failure I-Not_AE_Candidate
. O

5.19 O
Drug-Laboratory O
Test O
Interactions O
Accelerated B-OSE_Labeled_AE
prothrombin O
time O
, O
partial O
thromboplastin O
time O
, O
and O
platelet I-OSE_Labeled_AE
aggregation I-OSE_Labeled_AE
time I-OSE_Labeled_AE
; O
increased B-OSE_Labeled_AE
platelet I-OSE_Labeled_AE
count I-OSE_Labeled_AE
; O
increased B-OSE_Labeled_AE
factors O
II O
, O
VII O
antigen O
, O
VIII O
antigen O
, O
VIII O
coagulant O
activity O
, O
IX O
, O
X O
, O
XII O
, O
VII-X O
complex O
, O
II-VII-X O
complex O
, O
and O
beta I-OSE_Labeled_AE
- I-OSE_Labeled_AE
thromboglobulin I-OSE_Labeled_AE
; O
decreased B-OSE_Labeled_AE
levels I-OSE_Labeled_AE
of I-OSE_Labeled_AE
antifactor O
Xa O
and O
antithrombin I-OSE_Labeled_AE
III I-OSE_Labeled_AE
, O
decreased B-OSE_Labeled_AE
antithrombin I-OSE_Labeled_AE
III I-OSE_Labeled_AE
activity I-OSE_Labeled_AE
; O
increased B-OSE_Labeled_AE
levels O
of O
fibrinogen I-OSE_Labeled_AE
and O
fibrinogen O
activity I-OSE_Labeled_AE
; O
increased B-OSE_Labeled_AE
plasminogen I-OSE_Labeled_AE
antigen O
and O
activity I-OSE_Labeled_AE
. O

Increased B-OSE_Labeled_AE
thyroid I-OSE_Labeled_AE
- I-OSE_Labeled_AE
binding I-OSE_Labeled_AE
globulin I-OSE_Labeled_AE
( I-OSE_Labeled_AE
TBG I-OSE_Labeled_AE
) I-OSE_Labeled_AE
levels I-OSE_Labeled_AE
leading O
to O
increased B-NonOSE_AE
circulating I-NonOSE_AE
total I-NonOSE_AE
thyroid I-NonOSE_AE
hormone I-NonOSE_AE
levels I-NonOSE_AE
as O
measured O
by O
protein-bound O
iodine O
( O
PBI O
) O
, O
T4levels O
( O
by O
column O
or O
by O
radioimmunoassay O
) O
or O
T3levels O
by O
radioimmunoassay O
. O

T B-OSE_Labeled_AE
3 I-OSE_Labeled_AE
resin I-OSE_Labeled_AE
uptake I-OSE_Labeled_AE
is I-OSE_Labeled_AE
decreased I-OSE_Labeled_AE
, O
reflecting O
the O
elevated B-NonOSE_AE
TBG I-NonOSE_AE
. O

Free O
T4and O
free O
T3concentrations O
are O
unaltered O
. O

Women O
on O
thyroid O
replacement O
therapy O
may O
require O
higher O
doses O
of O
thyroid O
hormone O
. O

Other O
binding O
proteins O
may O
be O
elevated B-OSE_Labeled_AE
in O
serum O
, O
for O
example O
, O
corticosteroid I-OSE_Labeled_AE
binding I-OSE_Labeled_AE
globulin I-OSE_Labeled_AE
( I-OSE_Labeled_AE
CBG I-OSE_Labeled_AE
) O
, O
sex O
hormone-binding O
globulin O
( O
SHBG O
) O
, O
leading O
to O
increased B-NonOSE_AE
total I-NonOSE_AE
circulating I-NonOSE_AE
corticosteroids I-NonOSE_AE
and I-NonOSE_AE
sex I-NonOSE_AE
steroids I-NonOSE_AE
, O
respectively O
. O

Free O
hormone O
concentrations O
, O
such O
as O
testosterone B-OSE_Labeled_AE
and O
estradiol O
, O
may O
be O
decreased I-OSE_Labeled_AE
. O

Other O
plasma O
proteins O
may O
be O
increased B-OSE_Labeled_AE
( O
angiotensinogen/renin O
substrate O
, O
alpha-1-antitrypsin O
, O
ceruloplasmin I-OSE_Labeled_AE
) O
. O

Increased B-OSE_Labeled_AE
plasma I-OSE_Labeled_AE
high I-OSE_Labeled_AE
- I-OSE_Labeled_AE
density I-OSE_Labeled_AE
lipoprotein I-OSE_Labeled_AE
( I-OSE_Labeled_AE
HDL I-OSE_Labeled_AE
) O
and O
HDL2cholesterol O
subfraction O
concentrations O
, O
reduced B-OSE_Labeled_AE
low I-OSE_Labeled_AE
- I-OSE_Labeled_AE
density I-OSE_Labeled_AE
lipoprotein I-OSE_Labeled_AE
( I-OSE_Labeled_AE
LDL I-OSE_Labeled_AE
) I-OSE_Labeled_AE
cholesterol I-OSE_Labeled_AE
concentrations I-OSE_Labeled_AE
, O
increased B-OSE_Labeled_AE
triglyceride I-OSE_Labeled_AE
levels I-OSE_Labeled_AE
. O

Impaired B-OSE_Labeled_AE
glucose I-OSE_Labeled_AE
tolerance I-OSE_Labeled_AE
. O

